US Patent

US9320740 — Ceftolozane-tazobactam pharmaceutical compositions

Formulation · Assigned to Merck Sharp and Dohme LLC · Expires 2034-03-14 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions of ceftolozane and tazobactam in separate or combined unit dosage forms.

USPTO Abstract

Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.

Drugs covered by this patent

Patent Metadata

Patent number: US9320740
Jurisdiction: US
Classification: Formulation
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.